임상시험 관리 시스템 시장 규모, 점유율과 동향 분석 보고서 : 솔루션 유형별, 제공 모드별, 컴포넌트별, 최종 용도별, 지역별, 부문 예측(2026-2033년)

Clinical Trials Management System Market Size, Share & Trends Analysis Report By Solution Type, By Delivery Mode (Web & Cloud-based, On-premise), By Component (Software, Services), By End-user, By Region, And Segment Forecasts, 2026 - 2033

US $ 5,950 ￦ 8,981,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,491,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,510,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

임상시험 관리 시스템(CTMS) 시장 요약

세계의 임상시험 관리 시스템(CTMS) 시장 규모는 2025년에 23억 5,000만 달러로 추정되며, 2026-2033년에 CAGR 15.59%로 성장하며, 74억 달러에 달할 것으로 예측됩니다.

이러한 성장은 주로 임상시험 전반에 걸친 디지털 솔루션 도입 가속화, 임상시험의 복잡성 증가, 분산형 및 하이브리드 임상시험 모델에 대한 선호도 증가에 기인합니다.

또한 주요 업계 기업의 기술 업그레이드, 파트너십, 플랫폼 통합과 같은 전략적 노력과 세계 임상 연구 수의 꾸준한 증가가 결합되어 시장 규모가 더욱 확대될 것으로 예측됩니다. 임상시험 증가는 임상시험 관리 시스템 시장의 성장을 촉진하고 있습니다. 스폰서 및 CRO(임상시험수탁기관)는 복잡해지는 시험 내용, 다중기관 간 조정, 규제 관련 문서 관리에 대응하기 위해 강력한 플랫폼이 필요하기 때문입니다. 예를 들어 Invest India에 따르면 2024년 인도에서 등록된 신규 임상시험은 약 18,000건으로 2023년 대비 50% 증가하여 임상시험 활동의 급격한 증가가 두드러지고 있습니다.

마찬가지로 ClinicalTrials.gov에 등록되고 결과가 발표된 연구 수는 2021-2025년까지 전년 대비 꾸준히 증가하여 임상시험 결과의 투명성과 적시 공개에 대한 규제 당국의 관심이 높아지고 있음을 반영하고 있습니다. 이는 세계 보고 요건을 준수하고 스폰서들의 책임감을 강화하는 동시에 연구 마일스톤, 결과 제출, 규제 타임라인을 효율적으로 추적할 수 있는 디지털 시스템의 필요성을 더욱 강조하고 있습니다.

또한 생명과학 기업 및 의료기기 제조업체의 R&D 투자 증가와 급성 및 만성질환의 유병률 증가가 임상시험의 급격한 증가를 견인하고 있습니다. 이러한 추세는 다양한 임상시험의 효율적인 관리를 촉진하고, 궁극적으로 환자 결과 개선으로 이어지는 CTMS(임상시험 관리 시스템) 등의 솔루션 수요를 촉진할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 임상시험 관리 시스템 시장 변수, 동향 및 범위

제4장 임상시험 관리 시스템 시장 : 솔루션 유형별 추정·동향 분석

제5장 임상시험 관리 시스템 시장 : 컴포넌트별 추정·동향 분석

제6장 임상시험 관리 시스템 시장 : 제공 모드별 추정·동향 분석

제7장 임상시험 관리 시스템 시장 : 최종 용도별 추정·동향 분석

제8장 임상시험 관리 시스템 시장 : 지역별 추정·동향 분석, 솔루션 유형별, 컴포넌트별, 제공 형태별, 최종 용도별

제9장 경쟁 구도

KSA

영문 목차

영문목차

Clinical Trials Management System (CTMS) Market Summary

The global clinical trials management system (CTMS) market size was estimated at USD 2.35 billion in 2025 and is projected to reach USD 7.40 billion, growing at a CAGR of 15.59% from 2026 to 2033. This growth is primarily driven by the accelerated adoption of digital solutions across clinical trials, increasing trial complexity, and the growing preference for decentralized and hybrid trial models.

In addition, strategic initiatives by key industry players such as technology upgrades, partnerships, and platform integrations combined with a steady rise in the number of clinical studies globally, are expected to further fuel market expansion. The growing volume of clinical trials is driving the growth of the clinical trial management system market, as sponsors and CROs require robust platforms to manage increasing study complexity, multi-site coordination, and regulatory documentation. For instance, according to Invest India, around 18,000 new clinical trials were registered in India in 2024, marking a 50% increase compared to 2023, highlighting the surge in trial activity.

Similarly, the number of registered studies with posted results in ClinicalTrials.gov from 2021 to 2025 has shown a steady year-on-year increase, reflecting growing regulatory emphasis on transparency and timely disclosure of clinical trial outcomes. This highlights stronger compliance with global reporting requirements and increased accountability among sponsors, while also reinforcing the need for digital systems that can efficiently track study milestones, results submission, and regulatory timelines.

In addition, increasing R&D investments by life science and medical device companies, coupled with the growing prevalence of acute & chronic disorders, are driving the surge in clinical trials. This trend is expected to boost the demand for solutions such as CTMS, facilitating efficient management of diverse clinical trials and ultimately improving patient outcomes.

Global Clinical Trials Management System Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global clinical trials management systems market report based on solution type, component, delivery mode, end-use, and region:

• Solution Type Outlook (Revenue, USD Million, 2021 - 2033)
• Enterprise
• Site
• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Software
• Services
• Delivery Mode Outlook (Revenue, USD Million, 2021 - 2033)
• Web & Cloud Based
• On Premise
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical and Biotechnology Firms
• Medical Device Firms
• CROs & Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Solution Type
  • 1.1.2. Component
  • 1.1.3. Delivery mode
  • 1.1.4. End Use
  • 1.1.5. Regional scope
  • 1.1.6. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Solution type outlook
  • 2.2.2. Component outlook
  • 2.2.3. Delivery mode outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Trials Management System Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising number of clinical trials
    • 3.2.1.2. Increasing outsourcing of virtual or decentralized clinical trials
    • 3.2.1.3. Increasing demand for e-clinical solutions
    • 3.2.1.4. Integration of e-consent with other e-clinical solutions
    • 3.2.1.5. Rising number of virtual or decentralized clinical trials
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Rising data privacy and cybersecurity concerns
    • 3.2.2.2. Significant implementation costs
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenge analysis
• 3.3. Clinical Trials Management System Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
• 3.4. Case Study Insights
• 3.5. Technology Overview
  • 3.5.1. Changing Technology & Adoption

Chapter 4. Clinical Trials Management System Market: Solution Type Estimates & Trend Analysis

• 4.1. Solution Type Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Clinical Trials Management System Market by Solution Type Outlook
• 4.4. Descriptive Analysis
  • 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.5. Enterprise
  • 4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.6. Site
  • 4.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Clinical Trials Management System Market: Component Estimates & Trend Analysis

• 5.1. Component Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Clinical Trials Management System Market by Component Outlook
• 5.4. Software
  • 5.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.5. Services
  • 5.5.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Clinical Trials Management System Market: Delivery Mode Estimates & Trend Analysis

• 6.1. Delivery Modes Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Clinical Trials Management System Market by Delivery Modes Outlook
• 6.4. On-Premises
  • 6.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.5. Web & Cloud-Based
  • 6.5.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Clinical Trials Management System Market: End Use Estimates & Trend Analysis

• 7.1. Application Market Share, 2025 & 2033
• 7.2. Segment Dashboard
• 7.3. Global Clinical Trials Management System Market by Application Outlook
• 7.4. Pharmaceutical and Biotechnology Firms
  • 7.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 7.5. Medical Device Firms
  • 7.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 7.6. CROs & Others
  • 7.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 8. Clinical Trials Management System Market: Regional Estimates & Trend Analysis, By Solution Type, By Component, By Delivery Mode, By End Use

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Denmark
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.8. Norway
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization 2025
• 9.3. Key company market share analysis, 2025
• 9.4. Company Profiles,
  • 9.4.1. IQVIA, Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Medidata (Dassault Systemes)
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Oracle
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Datatrak International, Inc. (Rebranded as Fountayn in 2022)
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. SimpleTrials
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Ennov (Parexel's Informatics division separated to form Calyx in January 2021, and its Enterprise Technology division was acquired by Ennov in February 2024.)
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. RealTime Software Solutions, LLC
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Veeva Systems
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Wipro Limited
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. PHARMASEAL International Ltd.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Advarra Inc.
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. Clario (ERT and Bioclinica)
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. Merative
    • 9.4.13.1. Company overview
    • 9.4.13.2. Financial performance
    • 9.4.13.3. Product benchmarking
    • 9.4.13.4. Strategic initiatives
  • 9.4.14. Clinion
    • 9.4.14.1. Company overview
    • 9.4.14.2. Financial performance
    • 9.4.14.3. Product benchmarking
    • 9.4.14.4. Strategic initiatives
  • 9.4.15. Anju Software
    • 9.4.15.1. Company overview
    • 9.4.15.2. Financial performance
    • 9.4.15.3. Product benchmarking
    • 9.4.15.4. Strategic initiatives
  • 9.4.16. ICON, plc
    • 9.4.16.1. Company overview
    • 9.4.16.2. Financial performance
    • 9.4.16.3. Product benchmarking
    • 9.4.16.4. Strategic initiatives
  • 9.4.17. Suvoda LLC (in April 2025 merged with Greenphire)
    • 9.4.17.1. Company overview
    • 9.4.17.2. Financial performance
    • 9.4.17.3. Product benchmarking
    • 9.4.17.4. Strategic initiatives

관련자료